Abstract
The Glasgow Prognostic Score (GPS), neutrophil/lymphocyte ratio (NLR) and prognostic nutritional index (PNI) are prognostic parameters for malignancies. Additionally, serum squamous cell carcinoma antigen (SCC-Ag) and cytokeratin 19 fragments (CYFRA 21-1) are tumor markers for squamous cell carcinoma. In the present study, the prognostic importance of these markers in patients with resectable thoracic esophageal cancer was investigated. In this retrospective study, 84 enrolled patients diagnosed with resectable clinical stage I–III thoracic esophageal squamous cell carcinomas (ESCCs) underwent thoracic esophageal resection and three-field lymph node dissection at Tottori University Hospital between January 2007 and December 2013. The correlations among preoperative patient markers (GPS, NLR, PNI, SCC-Ag and CYFRA 21-1) and the occurrence of postoperative complications and patient survival were analyzed. The operative mortality was 2.4%, and morbidity was 42.9%. Strong correlations between occurrence of postoperative complications and open thoracotomy (P=0.083) and high-serum CYFRA 21-1 (P=0.007) were observed. In 15 patients with high-serum CYFRA 21-1, postoperative complications were detected in 11 of them (73.3%); on the other hand, complications occurred in 25 of 69 (36.2%) with low-serum CYFRA 21-1. The 5-year disease-free survival rate and 5-year overall survival rate of all the patients were 52.2 and 50.8%, respectively. Among the prognostic parameters, preoperative high NLR was determined to be a poor prognostic factor, independent of the tumor stage in the multivariate analysis. These results may indicate that, in patients with preoperative high-serum CYFRA 21-1, more attention should be paid to the occurrence of postoperative complications. Therefore, in such cases, anastomosis between blood vessels of the substitute esophagus and cervical vessels would be recommended. Furthermore, in patients with high preoperative NLR, effective adjuvant chemoradiotherapy should be considered to prolong the patients' survival, even of stage I or II patients.
Keywords: neutrophil/lymphocyte ratio, esophageal squamous cell carcinoma, cytokeratin 19 fragments, postoperative complication, survival
Introduction
The prognosis of patients with squamous cell carcinomas that occur in the thoracic esophagus remains poor. Even following curative resection, numerous patients die due to tumor recurrence. Lymph nodes metastases to the neck, chest, and abdomen have been detected frequently in resected specimens from patients with thoracic esophageal squamous cell carcinoma (ESCC) (1). Thus, subtotal esophagectomy plus three-field lymph node dissection (cervical, thoracic and abdominal) has been introduced as an effective therapeutic strategy for the treatment of localized thoracic ESCC in Japan (2,3). However, due to high morbidity and mortality rates following thoracotomy and laparotomy for patients with thoracic ESCCs, the use of surgery to treat this condition has been limited (4,5). A number of institutes have excluded patients with T4 cancer (invasion to the adjacent organs), with distant metastasis (to the lung, liver, bone, or extended lymph nodes), with poor Eastern Cooperative Oncology Group Performance Status (ECOG-PS), with severe organ dysfunction, including the cardiopulmonary system, liver, and kidney, or with an advanced age (>75 years old) from surgical treatments (5,6). Therefore, to set in place the best treatment program for patients with operable thoracic ESCC, it is very important to evaluate factors that indicate the occurrence of postoperative complications and prognosis of patients with thoracic ESCC preoperatively.
With the exception of a subjective evaluation of ECOG-PS, patients have been evaluated objectively through the Glasgow Prognostic Score (GPS), calculated by the combination of C-reactive protein (CRP) and albumin (ALB), the neutrophil/lymphocyte ratio (NLR) and the prognostic nutritional index (PNI), which have been reported to be important prognostic markers in cancer patients (7–15). These markers represent the patients' chronic systemic inflammation, immune status and nutritional condition. Furthermore, serum squamous cell carcinoma antigen (SCC-Ag) and cytokeratin 19 fragments (CYFRA 21-1) have been reported as good markers of ESCC progression (16–18).
Thus, in the present study, the objective preoperative markers, GPS, NLR, PNI, serum SCC-Ag and CYFRA 21-1, were retrospectively analyzed in patients with operable thoracic ESCCs, and an evaluation was made as to whether these factors are good markers of complications and prognosis in these patients.
Materials and methods
Patients
A total of 84 patients with clinical stage I–III thoracic ESCCs underwent thoracic esophagectomy plus three-field lymph node dissection (cervical, thoracic and abdominal) at Tottori University Hospital during January 2007 and December 2013. The clinical tumor stages were routinely diagnosed by esophagogastroscopy, computed tomography (CT) scanning, an endoscopic ultrasound and positron emission topography. Clinical examination, pulmonary function tests, electrocardiography, echocardiography and exercise tolerance testing were used to assess the validity of the surgical procedures for the patients. These 84 patients with potentially resectable thoracic ESCCs were deemed to be physiologically fit for surgery.
The average age of the patients was 65.7 years old (range: 49–78 years). A total of 73 patients were males, and 11 were females. Informed consent was obtained from all the patients prior to treatment. All investigations reported in the present study were conducted in conformity with the recommendations of the Declaration of Helsinki. All patients were followed up at Tottori University Hospital until September 2015. The median follow-up period was 35.5 months (range, 1–102 months).
Operation
Traditional right antero-lateral thoracotomy with laparotomy (open method) was routinely performed in our institute at Tottori University Hospital between January 2007 and August 2009. Thoracoscopic thoracic esophagectomy in the prone position was introduced in September 2009 (the thoracoscopic method). However, the use of right anterolateral thoracotomy was indicated for those cases with strong adhesion between the lungs and the pleura. The open method was performed on 33 patients, and the thoracoscopic method was performed on 51. To diagnose the safety of resected proximal margin of the esophagus, intraoperative histological analysis of the frozen section of the proximal margin was routinely performed. The stomach was used as the substitute esophagus in 74 patients, but in 10 patients with double cancers (esophageal and gastric cancer) or for gastrectomized cases, the jejunum was elongated to cervical esophagus or pharynx via an ante-sternum root.
Chemotherapy
S-1 adjuvant chemotherapy has been introduced at Tottori University Hospital for patients with stage II or III ESCCs. According to the results from the Japan Clinical Oncology Group (JCOG) studies 9204 and 9907 (19,20), since 2010, neoadjuvant chemotherapy (NAC) with cisplatin plus 5-fluorouracil (5-FU) has been offered to patients who have been diagnosed as clinical stages II and III in our institute. Therefore, chemotherapy was performed for 45 patients (adjuvant, 7; NAC, 27; and both, 11).
Blood samples
Blood samples were obtained from each patient routinely prior to chemotherapy or surgery. Serum levels of ALB, CRP, the total lymphocyte count, serum SCC-Ag and CYFRA 21-1 were recorded. Patients with normal CRP (<1.0 mg/dl) and ALB (≥3.5 g/dl) levels had a GPS of 0, and were classified as the low GPS group. Patients with either one abnormal factor (GPS=1), or both abnormal factors (GPS=2) were classified as the high GPS group. An NLR ≥3 was considered as abnormal (21). The PNI [PNI=10 × serum ALB concentration (g/dl)+0.005 × lymphocyte count (number/mm3) in peripheral blood] cut-off value was determined to be 50 (22). According to the manufacturer's protocols, the normal upper limit was 1.5 µg/l for SCC-Ag and 3.3 ng/ml for CYFRA 21-1 (16–18). Patients were divided into low and high subsets according to the normal upper limit of the prognostic factors. Patients' prognostic factors were obtained prior to treatment (surgery or chemotherapy).
Pathological analysis
According to the International Union Against Cancer (UICC) tumor-lymph node-metastasis (TNM) classification for esophageal cancer (23), 29 patients were graded with stage I, 22 with stage II, and 33 with stage III cancer. An R0 resection, defined as complete tumor excision, was performed for all patients.
Statistical analysis
The Mann-Whitney U test, Chi-squared test and Fisher's exact probability test were used to compare the clinicopathological characteristics of the two groups. Spearman's rank correlation coefficient was used to assess the correlation between the two numerical parameters. A strong correlation between the parameters and occurrence of postoperative complications was estimated using the logistic-regression analysis. Long-term survival was calculated using the Kaplan-Meier method, and the prognostic difference between the two groups was compared using the log-rank test. Multivariate Cox regression analysis was used for all parameters that were found to be significant using univariate analysis. P<0.05 was considered to indicate a statistically significant difference.
Results
The clinical characteristics of the 84 patients are shown in Table I. Surgical complications were detected in 36 patients (morbidity was 42.9%). Two patients died due to surgical complications, and the mortality was 2.4%. Anastomotic leakage was detected in 25 patients, pneumonia in four, chylothorax in four, and necrosis of the substituted esophagus was observed in three.
Table I.
Clinical characteristics of 84 patients with thoracic esophageal squamous cell carcinomas who underwent esophagectomy and three-field lymph node dissection.
| Characteristic | Clinical data |
|---|---|
| Age (mean; median, range, years) | 65.7 (66, 49–78) |
| Gender (male/female) | 73/11 |
| Operation time (mean; median, range, minutes) | 649 (625, 420–984) |
| Intraoperative blood loss (mean; median, range, ml) | 475.3 (320, 10–3, 020) |
| Number of dissected lymph nodes (Mean, median, range) | 50.6 (49, 14–110) |
| Histological tumor stage (I/II/III) | 29/22/33 |
| Postoperative complications (yes/no) | 36/48 |
| Postoperative hospital stay (mean; median, range, days) | 50.3 (31, 10–478) |
A total of 77 patients were GPS=0, six were GPS=1 and one was GPS=2. Therefore, high GPS was detected in seven of the patients and the remaining 77 were characterized as low GPS. The mean NLR was 2.3 (median 2.3, range: 0.6–5.8). Twenty-six patients were classified in the high NLR group (NLR ≥3), and 58 were in the low NLR group. The mean PNI was 51.2 (median 50.6, range: 36.4–72.2). Fifty patients were classified in the high PNI group (PNI ≥50), and 34 were in the low PNI group. The mean SCC-Ag was 1.6 µg/l (median 1.2, range: 0.3–9.1). Thirty-two patients were classified in the high SCC-Ag group (SCC-Ag ≥1.5 µg/l), and 52 were in the low SCC-Ag group. The mean CYFRA 21-1 was 2.3 ng/ml (median 1.2, range: 0.3–9.1). Fifteen patients were classified in the high CYFRA 21-1 group (CYFRA 21-1 ≥3.3 ng/ml) and 69 in the low CYFRA 21-1 group. Thirteen factors that were thought to correlate with the occurrence of postoperative complications were analyzed using the logistic regression test (Table II). The median values of patient age, operation time, intraoperative blood loss and number of dissected lymph nodes were used as cut-offs. Strong correlations between the occurrence of postoperative complications and open thoracotomy (P=0.083) and high-serum CYFRA 21-1 (P=0.007) were observed. In 15 patients with high-serum CYFRA 21-1, postoperative complications were detected in 11 (73.3%); on the other hand, in 69 patients with low-serum CYFRA 21-1, postsurgical complications were detected in 25 (36.2%). A positive correlation was detected between SCC-Ag and CYFRA 21-1 (P=0.359, P=0.001), and a strong negative correlation was detected between NLR and PNI (P=−0.449, P<0.001).
Table II.
Multivariate analysis of predictors of postoperative complications.
| P-value | Odds ratio | 95% confidence interval | |
|---|---|---|---|
| Advanced age | 0.608 | 0.741 | 0.236–2.326 |
| Male | 0.438 | 0.520 | 0.100–2.712 |
| Neoadjuvant chemotherapy | 0.383 | 1.848 | 0.466–7.299 |
| Open thoracotomy | 0.083 | 5.155 | 0.806–33.333 |
| Long operation time | 0.166 | 2.421 | 0.693–8.475 |
| Large intraoperative blood loss | 0.705 | 0.574 | 0.175–3.257 |
| Large number of dissected lymph nodes | 0.168 | 0.842 | 0.108–1.083 |
| Tumor stage III | 0.127 | 0.395 | 0.120–1.301 |
| High GPS | 0.254 | 3.300 | 0.425–25.641 |
| High NLR | 0.533 | 0.593 | 0.115–3.058 |
| Low PNI | 0.681 | 0.767 | 0.217–2.710 |
| High SCC-Ag | 0.103 | 0.324 | 0.084–1.253 |
| High CYFRA 21–1 | 0.007 | 9.346 | 1.825–47.619 |
GPS, Glasgow Prognostic Score; NLR, neutrophil/lymphocyte ratio; PNI, prognostic nutritional index; SCC-Ag, squamous cell carcinoma antigen; CYFRA 21-1, cytokeratin 19 fragments.
The 5-year disease-free survival (DFS) rate and 5-year overall survival (OS) rate of all patients were 52.2 and 50.8%, respectively. The long-term outcomes were compared between the two groups (Table III). Postoperative complications did not affect DFS or OS. Furthermore, the SCC-Ag and CYFRA 21-1 values did not correlate with survival. NLR and PNI were recognized as strong prognostic factors from the univariate analysis. Table IV shows the multivariate survival analysis of the factors that were detected as significant in DFS using univariate analysis (Table III). Among the prognostic factors, high NLR was identified as a poor prognostic factor independent of the tumor stage.
Table III.
The 5-year disease-free survival rate and 5-year overall survival rate of the two groups.
| Parameters | No. | 5-year DFS (%) | P-value | 5-year OS (%) | P-value |
|---|---|---|---|---|---|
| Age | |||||
| High | 45 | 56.2 | 0.486 | 46.3 | 0.478 |
| Low | 39 | 48 | 55.1 | ||
| Gender | |||||
| Male | 73 | 50.3 | 0.365 | 48.1 | 0.248 |
| Female | 11 | 63.6 | 69.3 | ||
| Tumor stage | |||||
| I and II | 51 | 73.8 | <0.001 | 67.9 | <0.001 |
| III | 33 | 19.6 | 19.5 | ||
| Postoperative complication | |||||
| Yes | 36 | 49.4 | 0.833 | 44.4 | 0.13 |
| No | 48 | 53.6 | 55.5 | ||
| GPS | |||||
| High | 7 | 85.7 | 0.123 | 85.7 | 0.238 |
| Low | 77 | 49 | 49.0 | ||
| NLR | |||||
| High | 26 | 28.8 | <0.001 | 28.1 | <0.001 |
| Low | 58 | 62.8 | 60.2 | ||
| PNI | |||||
| High | 50 | 60.3 | 0.026 | 53.6 | 0.017 |
| Low | 34 | 39.5 | 43.0 | ||
| SCC-Ag | |||||
| High | 32 | 50.9 | 0.985 | 50.8 | 0.871 |
| Low | 52 | 52.9 | 50.7 | ||
| CYFRA 21-1 | |||||
| High | 15 | 40 | 0.271 | 42.8 | 0.956 |
| Low | 69 | 55.1 | 51.3 |
DFS, disease-free survival; OS, overall survival; GPS, Glasgow Prognostic Score; NLR, neutrophil/lymphocyte ratio; PNI, prognostic nutritional index; SCC-Ag, squamous cell carcinoma antigen; CYFRA 21-1, cytokeratin 19 fragments.
Table IV.
Multivariate disease-free survival analysis of patients.
| Parameter | P-value | Odds ratio | 95% confidence interval |
|---|---|---|---|
| Tumor stage III | <0.001 | 5.714 | 2.793–11.628 |
| High NLR | 0.03 | 2.426 | 1.091–5.394 |
| Low PNI | 0.369 | 1.431 | 0.655–3.125 |
NLR, neutrophil/lymphocyte ratio; PNI, prognostic nutritional index.
Discussion
Esophagectomy plus three-field lymph node dissection has been the standard surgical regimen for the treatment of thoracic ESCCs. However, high morbidity or mortality and poor prognosis of patients should be considered prior to opting for surgical treatment. In the present study, postoperative morbidity and mortality were 42.9 and 2.4%, respectively. In these cases of high morbidity, it was determined that the preoperative high-serum CYFRA 21-1 was a clear indicator of the occurrence of postoperative complications. CYFRA 21-1 is a cytoskeleton marker with a low-molecular weight (40 kDa), and is one of the serum tumor markers of squamous cell carcinomas (16–18). Recently, Vercauteren et al (24) reported that increased levels of serum CYFRA 21-1 were correlated with pulmonary fibrosis. Thus, a high-serum CYFRA 21-1 level may correlate with tissue disorder at the anastomotic site, such as non-development of micro-vascularization. A detailed study is expected to be performed regarding the biological significance of serum CYFRA 21-1. In patients with high-serum CYFRA 21-1, supercharged microvascular anastomoses between the cervical neck and the substitute esophagus should be considered to avoid the occurrence of anastomotic leakage.
Tumor stage III, high NLR and low PNI were identified to be poor DFS and OS factors in patients with operable thoracic ESCCs. These findings have been reported previously (25–27). Specifically, it our study has revealed, via the multivariable analysis of our present cohort, that NLR was an important prognostic marker in patients with thoracic ESCCs independent of the tumor stage. Han et al (28) identified that high pretreatment NLRs were significantly associated with high levels of neutrophil infiltration and low CD3+ T-cell infiltration into glioblastomas, and a strong correlation with shorter survival times in patients with glioblastoma. Neutrophil infiltration into various tumors serves an important role in stimulating tumor growth, angiogenesis and metastasis (29,30). In addition, neutrophils may suppress immune function by inhibiting the cytotoxic activity of CD8+ T-cells and natural killer cells by enhancing the suppressive activities of CD4+ suppressor T cells in the infiltrating tissues. These findings may indicate that the pretreatment NLR measured in peripheral blood samples from patients will be a useful marker of local host immunity.
This study had a number of limitations. First, the number of patients with resectable thoracic ESCCs in our series was small. Secondly, our study was a retrospective analysis, and there is a possibility that the results from our study may have bias. However, our results do indicate that, in patients with preoperative high-serum CYFRA 21-1, more attention will need to be paid to the occurrence of postoperative complications. Therefore, in such cases, anastomosis between blood vessels of the substitute esophagus and cervical vessels should be recommended. Additionally, our results may indicate that, in patients with high preoperative NLR, effective adjuvant chemoradiotherapy should be considered to prolong the patients' survival, even of stage I or II patients.
Glossary
Abbreviations
- ALB
albumin
- CRP
C-reactive protein
- CT
computed tomography
- CYFRA 21-1
cytokeratin 19 fragments
- DFS
disease-free survival
- ECOG-PS
Eastern Cooperative Oncology Group Performance Status
- ESCC
esophageal squamous cell carcinoma
- GPS
Glasgow Prognostic Score
- NAC
neoadjuvant chemotherapy
- NLR
neutrophil/lymphocyte ratio
- OS
overall survival
- PNI
prognostic nutritional index
- SCC-Ag
squamous cell carcinoma antigen
References
- 1.Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232:225–232. doi: 10.1097/00000658-200008000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Tachibana M, Kinugasa S, Yoshimura H, Shibakita M, Tonomoto Y, Dhar DK, Nagasue N. Clinical outocomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg. 2005;189:98–109. doi: 10.1016/j.amjsurg.2004.10.001. [DOI] [PubMed] [Google Scholar]
- 3.Shimada H, Okazumi S, Matsubara H, Nabeya Y, Shiratori T, Shimizu T, Shuto K, Hayashi H, Ochiai T. Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg. 2006;30:1441–1449. doi: 10.1007/s00268-005-0462-6. [DOI] [PubMed] [Google Scholar]
- 4.Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, Nakatani K, Ishido K, Naruke A, Ryu T. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res. 2009;3:153–161. [PMC free article] [PubMed] [Google Scholar]
- 5.Grimm JC, Valero V, III, Molena D. Surgical indications and optimization of patients for resectable esophageal malignancies. J Thorac Dis. 2014;6:249–257. doi: 10.3978/j.issn.2072-1439.2013.11.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Reed CE. Surgical management of esophageal carcinoma. The Oncologist. 1999;4:96–105. [PubMed] [Google Scholar]
- 7.Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Cho SH, Chung IJ. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer. 2011;11:489. doi: 10.1186/1471-2407-11-489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Urba S, Gatz J, Shen W, Hossain A, Winfree K, Koustenis A, Peterson P, Cohen EE. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: Analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy. Oral Oncol. 2012;48:723–729. doi: 10.1016/j.oraloncology.2012.02.016. [DOI] [PubMed] [Google Scholar]
- 9.McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534–540. doi: 10.1016/j.ctrv.2012.08.003. [DOI] [PubMed] [Google Scholar]
- 10.Kishiki T, Masaki T, Matsuoka H, Kobayashi T, Suzuki Y, Abe N, Mori T, Sugiyama M. Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer. Am J Surg. 2013;206:234–240. doi: 10.1016/j.amjsurg.2012.07.051. [DOI] [PubMed] [Google Scholar]
- 11.Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288–1295. doi: 10.1038/bjc.2011.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007;73:215–220. doi: 10.1159/000127412. [DOI] [PubMed] [Google Scholar]
- 13.Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S, Tabuchi T. Evaluation of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol. 2010;102:742–747. doi: 10.1002/jso.21725. [DOI] [PubMed] [Google Scholar]
- 14.Nozoe T, Kohno M, Iguchi T, Mori E, Maeda T, Matsukuma A, Ezaki T. The prognostic nutritional index can be a prognostic indicator in colorectal carcinoma. Surg Today. 2012;42:532–535. doi: 10.1007/s00595-011-0061-0. [DOI] [PubMed] [Google Scholar]
- 15.Ikeguchi M, Urushibara S, Shimoda R, Yamamoto M, Maeta Y, Ashida K. Inflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancer. World J Surg Oncol. 2014;12:210. doi: 10.1186/1477-7819-12-210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Tsuchita Y, Onda M, Miyashita M, Sasajima K. Serum level of cytokeratin 19 fragment (CYFRA 21–1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus. Med Oncol. 1999;16:31–37. doi: 10.1007/BF02787356. [DOI] [PubMed] [Google Scholar]
- 17.Nabeya Y, Shimada H, Okazumi S, Matsubara H, Gunji Y, Suzuki T, Ochiai T. Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma. Cancer. 2002;94:940–949. doi: 10.1002/cncr.10267. [DOI] [PubMed] [Google Scholar]
- 18.Cao X, Zhang L, Feng GR, Yang J, Wang RY, Li J, Zheng XM, Han YJ. Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma. J Transl Med. 2012;10:197. doi: 10.1186/1479-5876-10-197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 2003;21:4592–4596. doi: 10.1200/JCO.2003.12.095. [DOI] [PubMed] [Google Scholar]
- 20.Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Inoue M, Yamamura T. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep. 2012;28:446–452. doi: 10.3892/or.2012.1847. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Duan H, Zhang X, Wang FX, Cai MY, Ma GW, Yang H, Fu JH, Tan ZH, Meng YQ, Fu XY, et al. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma. World J Gastroenterol. 2015;21:5591–5597. doi: 10.3748/wjg.v21.i18.5591. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Sun P, Zhang F, Chen C, An X, Li YH, Wang FH, Zhu ZH. Comparison of the prognostic values of various nutritional parameters in patients with esophageal squamous cell carcinoma from Southern China. J Thorac Dis. 2013;5:484–491. doi: 10.3978/j.issn.2072-1439.2013.08.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Sobin LH, Wittekind CH. UICC TNM classification of malignant tumours. 6th. Hoboken, New Jersey: John Wiley & Sons; 2002. [Google Scholar]
- 24.Vercauteren IM, Verleden SE, McDonough JE, Vandermeulen E, Ruttens D, Lammertyn EJ, Bellon H, De Dycker E, Doomes C, Yserbyt J, et al. CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients. Exp Lung Res. 2015;41:459–465. doi: 10.3109/01902148.2015.1073407. [DOI] [PubMed] [Google Scholar]
- 25.Hirahara N, Matsubara T, Hayashi H, Takai K, Fujii Y, Tajima Y. Impact of inflammation-based prognostic score on survival after curative thoracoscopic esophagectomy for esophageal cancer. Eur J Surg Oncol. 2015;41:1308–1315. doi: 10.1016/j.ejso.2015.07.008. [DOI] [PubMed] [Google Scholar]
- 26.Yodying H, Matsuda A, Miyashita M, Matsumoto S, Sakurazawa N, Yamada M, Uchida E. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outocomes of esophageal cancer: A systematic review and meta-analysis. Ann Surg Oncol. 2016;23:646–654. doi: 10.1245/s10434-015-4869-5. [DOI] [PubMed] [Google Scholar]
- 27.Liu JS, Huang Y, Yang X, Feng JF. A nomogram to predict prognostic values of various inflammatory biomarkers in patients with esophageal squamous cell carcinoma. Am J Cancer Res. 2015;5:2180–2189. [PMC free article] [PubMed] [Google Scholar]
- 28.Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer. 2015;15:617. doi: 10.1186/s12885-015-1629-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, Deryugina EI. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol. 2011;179:1455–1470. doi: 10.1016/j.ajpath.2011.05.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Dumitru CA, Lang S, Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: Mechanisms and consequences for tumor progression. Semin Cancer Biol. 2013;23:141–148. doi: 10.1016/j.semcancer.2013.02.005. [DOI] [PubMed] [Google Scholar]